Daniel Iosifescu
Professor of Psychiatry
Papers
Trials
Key Impact
Noted for clinical and translational research on ketamine for treatment‑resistant depression, integrating neurocognitive, neuroimaging and immunological biomarkers to predict and understand treatment response.
Background & Research
Daniel V. Iosifescu is a clinician‑researcher in psychiatry whose work focuses on rapid‑acting antidepressant treatments and the biological mechanisms underlying treatment‑resistant mood disorders. He has played a central role in multi‑site randomized controlled trials evaluating the antidepressant efficacy of ketamine in treatment‑resistant major depressive disorder, and in secondary studies that examine differential effects in anxious versus non‑anxious depression. His clinical trial work includes systematic assessment of symptomatic outcomes alongside careful characterisation of cognitive effects and safety profiles.
In parallel with clinical trials, Iosifescu has contributed to translational investigations probing neural and peripheral biomarkers of response. His publications include studies of ketamine's modulation of neural responses to emotional perception, neurocognitive sequelae and their relationship to antidepressant benefit, and altered peripheral immune signatures that correlate with and may predict treatment outcome. Collectively his work aims to refine patient selection, clarify mechanisms of action for rapid‑acting therapies, and inform safer, more personalised approaches to treating refractory mood disorders.